TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05313568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: static stretching
Description: The stretch will be done by placing both feet on a raised platform, lowering the heel off the platform without touching the ground, and held in this position to perform a static stretch. They will perform 5 repetitions, 15 seconds of rest and 1 minute of stretching.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: static stretching
Description: The stretch will be done by placing both feet on a raised platform, lowering the heel off the platform without touching the ground, and held in this position to perform a static stretch. They will perform 5 repetitions, 15 seconds of rest and 1 minute of stretching.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: static stretching
Description: The stretch will be done by placing both feet on a raised platform, lowering the heel off the platform without touching the ground, and held in this position to perform a static stretch. They will perform 5 repetitions, 15 seconds of rest and 1 minute of stretching.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self massage
Description: In addition to the self-stretching application, plantar self-massage will be applied. Plantar self massage will be shown to the participants by the physiotherapist with a 7 cm spiky massage ball. Then, participants will be asked to self-massage the plantar sole of the foot for 5 minutes with a 7 cm spiky massage ball.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Stimulation
Description: In addition to the self-stretching application, manual stimulation will be applied.~Manual protocol:~A) Pressure will be applied in each interdigital space and on the longitudinal arch with shear in the longitudinal direction (5 repetitions of 10 seconds each).~B) Pressure with transverse shear on the metatarsal heads (5 repetitions of 5 seconds each) C) Static pressure will be applied to the first and fifth metatarsal head, center of the midfoot, and heel (5 repetitions per 10-second period each).
Study: NCT04833894

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod IV
Description: Intravenous infusion of Efgartigimod
Study: NCT06646822

Intervention type: OTHER
Intervention: questionnaire
Description: observational study
Study: NCT04955834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin degludec injection
Description: long-acting insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tresiba®
Description: long-acting insulin
Study: NCT05254639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DONEPEZIL
Description: 5 mg daily for 4 weeks + 10 mg daily for 12 weeks according to tolerance or efficacy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: 5 mg daily for 4 weeks + 10 mg daily for 12 weeks according to tolerance or efficacy
Study: NCT06377631

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine
Description: The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
Study: NCT06434948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Ethyl Esters 4 g
Description: 4 grams = 4 capsules, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Ethyl Esters 2 g
Description: 2 grams = 2 capsules, once daily
Study: NCT04994496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two-week web-based self-help intervention based on principles of positive psychology
Description: The web-based self-help intervention consists of 14 exercises based on the following positive psychology domains: personal strengths, pleasure, gratitude, engagement (flow, mindfulness) and positive relationships.~The (partly interactive) exercises are created to be implemented by the participants themselves without support of a therapist.~Before starting the intervention, the participants are told that they will receive a daily email with an instruction for a short exercise over the period of two weeks. The participants are instructed to complete the exercises every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Two-week web-based text messages containing fun facts
Description: The web-based sham intervention consists of 14 text messages containing random interesting facts (fun facts).~Before starting the sham intervention, the participants are told that they will receive a daily email with a text message to read every over the period of two weeks. The participants are instructed to read these text messages every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)
Study: NCT06053034

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Solio alpha cure plus
Description: The SOLIO Alfa Cure Plus is the only home-use device with FDA clearance that uses the proprietary synergy of three energy sources (IR, RF, and LLLT), and this study aims to assess the SOLIO Alfa Cure Plus's efficiency in providing pain relief. This technology is the first noninvasive and patented home RF device. SOLIO Alfa Cure Plus uses continuous RF, the internal controller reduces the RF power while reaching the treatment temperature of 39- 42 Celsius.The SOLIO Alfa Cure Plus Device is a round device equipped with a strap for hand holding, it is to be used while connected to a socket. The device is used by an assistant (usually a family member) on the participant's back for 20 minutes while moving it around in circles on the lower back.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Solio alpha cure plus
Description: The SOLIO Alfa Cure Plus is the only home-use device with FDA clearance that uses the proprietary synergy of three energy sources (IR, RF, and LLLT), and this study aims to assess the SOLIO Alfa Cure Plus's efficiency in providing pain relief. This technology is the first noninvasive and patented home RF device. SOLIO Alfa Cure Plus uses continuous RF, the internal controller reduces the RF power while reaching the treatment temperature of 39- 42 Celsius.The SOLIO Alfa Cure Plus Device is a round device equipped with a strap for hand holding, it is to be used while connected to a socket. The device is used by an assistant (usually a family member) on the participant's back for 20 minutes while moving it around in circles on the lower back.
Study: NCT05048849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901(S protein with adjuvant)
Description: Approximately 500 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
Study: NCT06469385

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ENS-002
Description: Live biotherapeutic product (LBP) consisting of commensal, clonal, non-pathogenic bacteria.~Low Dose ENS-002 High Dose ENS-002
Study: NCT05169970

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Patients with a low or intermediate risk Decipher score will receive radiation targeting the seminal prostate and seminal vesicles to a dose of 40 Gy in 5 fractions delivered every other day.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Patients with high risk Decipher scores will receive radiation targeting the prostate and seminal vesicles to a dose of 40 Gy in 5 fractions with a simultaneous integrated boost to 45 Gy of any dominant intraprostatic lesion as well as radiation to the pelvic lymph nodes to a dose of 25 Gy in 5 fractions delivered every other day.
Study: NCT05818150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embosphere Microspheres
Description: Embolic Agent: Embosphere Microspheres

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Corticosteroid injection
Study: NCT06377631

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
Study: NCT05567796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cagrilintide
Description: Cagrilintide will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Cagrilintide will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will recieve semaglutide subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Participants will recieve semaglutide subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cagrilintide
Description: Participants will receive placebo matched to cagrilintide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo cagrilintide
Description: Participants will receive placebo matched to cagrilintide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo semaglutide
Description: Participants will receive placebo matched to semaglutide.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo semaglutide
Description: Participants will receive placebo matched to semaglutide.
Study: NCT05377905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microneedle Array Doxorubicin (MNA-D)
Description: The Microneedle array patch is loaded/prepared with a total dose of 50 micrograms of Doxorubicin and is applied to a single selected cSCC remnant for a period of 20 minutes for a total of 4 weekly applications
Study: NCT06652672

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Organ-sparing surgery
Description: Endoscopy-assisted laparoscopic/robotic wedge resection and sentinel lymph node biopsy using submucosal injection of ICG.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care segmental resection
Description: Standard of care segmental resection of the affected part of the colon including removal of regional lymph nodes.
Study: NCT06661876

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 5 Gray Whole Heart external beam radiotherapy
Description: EBRT will be delivered with photon energies restricted to 6 Megavoltage (MV) using intensity modulated radiotherapy (IMRT) or Volumetric modulated arc therapy (VMAT). Patients will be treated with a single fraction treatment up to a dose of 5Gy prescribed to the 95% PTV-encompassing isodose line (PTVD95% ≥5Gy). The near-maximum dose is limited to 5.35Gy (PTV D2% ≤ 5.35Gy). The treatment can be performed both as an inpatient or outpatient procedure.
Study: NCT06003582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Parent Support
Description: Therapeutic Intervention
Study: NCT04945239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Amplification of Positivity Training (6 Sessions)
Description: 6 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management Training (6 Sessions)
Description: 6 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for activity exercises designed to decrease stress.
Study: NCT06181721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnipod 5 Automated Glucose Control System
Description: The Omnipod 5 Automated Glucose Control System will provide automated insulin delivery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnipod 5 Automated Glucose Control System
Description: The Omnipod 5 Automated Glucose Control System will provide automated insulin delivery
Study: NCT06674681

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HPV Self-Collection
Description: HPV self-collection program for in-clinic and mailed cervical cancer screening.
Study: NCT05819931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical In-Exsufflator treatment
Description: The Mechanical In-Exsufflator (MIE) is a device that alternately inhales and exhales air and amplifies the respiratory cycles in flow and pressure. 15 breathing cycles (about 3 minutes) are recommended each day.~Patients will practice the MIE daily independently and/or carried out by his physiotherapist (PT) during PT sessions.~The MIE is prescribed by the neurologist or pulmonologist and is covered by social security in France. It is gifted by an external service provider.~The Peak-Flow Cough is considered as the standardized score retaining the best of 3 consecutive measurements by Peak-Flow, a small portable device for personal use, which measures the maximum expiratory flow reached by the patient at the moment when the breath is most powerful.~The patient is his own control. At baseline, the patient will be treated as usual. He will be asked to read the Peak-Flow Cough measures. The PT will also perform the Peak flow measurement at each patient visit.
Study: NCT06684288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Access flap surgery
Description: Granulation tissue attached to the alveolar bone was excised to ensure complete access and optimal visibility of the root surfaces. In addition, instrumentation was performed using a combination of ultrasonic and hand instruments, and no alveolar bone modification was undertaken during the flap procedure. Subsequently, the mucoperiosteal flap was repositioned and primarily closed with proximal simple sutures employing monofilament suture material (5/0 Propilen, Dogsan, Türkiye). Patients were given post-operative recommendations; however, no medication was prescribed.
Study: NCT04959890

Intervention type: GENETIC
Intervention: Strimvelis
Description: This non-interventional, retrospective, methodology study will use peripheral blood and bone marrow samples previously taken from subjects treated with gRV-GT. The study does not require subjects to undergo any further treatment, intervention or blood withdrawal. Eligible samples will be shipped to a central laboratory and will undergo DNA extraction prior to S-EPTS/LM-PCR analysis. Each analysis run will include a control DNA sample and up to four subject samples. Each sample will be analysed in triplicate.
Study: NCT06759350

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy isoflavone supplement
Description: 2 capsules containing 10 mg natural tocotrienols, 40 mg soy isoflavonoids, 540 mg calcium, vitamin D IU.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (placebo) group
Description: 2 placebo capsules containing a multivitamin compound.
Study: NCT06761664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platysma Exercise Group
Description: The participants in this group will perform a platysma exercise for 7 days following third molar extraction surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (Standard treatment)
Description: Participants in this group will receive routine treatment following third molar extraction.
Study: NCT06764368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab + Apatinib
Description: Induction Phase:~Subjects will receive Adebrelimab (1200 mg, Day 1) + Etoposide (100 mg/m2, Days 1-3) + Carboplatin (AUC = 4-5, Day 1) / Cisplatin (75 mg/m2, Day 1) (as determined by the investigator) + Apatinib (250 mg, orally, once daily) in 3-week cycles (Q3W) for 4 to 6 cycles.~Maintenance Phase:~Adebrelimab (1200 mg, Day 1) + Apatinib (250 mg, orally, once daily) will be administered for 1 year or until one of the following occurs: disease progression, intolerable toxicity, withdrawal of informed consent by the subject, voluntary withdrawal from the study, or other protocol-specified reasons.
Study: NCT06764069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor Lead
Description: The Glucotrack Sensor Lead will be inserted into the subclavian vein, using a Seldinger technique, where it will continuously measure blood glucose levels.
Study: NCT06764849

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CONVENTIONAL OPEN EXCISIONAL HEMORRHOIDECTOMY
Description: Hemorrhoidectomy performed based on the conventional technique described by Milligan-Morgan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MINIMALLY INVASIVE OPEN EXCISIONAL HEMORRHOIDECTOMY
Description: Hemorrhoidectomy performed based on the tecnique described by Milligan Morgan, using a minimally invasive approach.
Study: NCT05501483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 45 mg
Description: Starts with 45 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: Starts with 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 7 MG
Description: Starts with 3 mg daily for the first 2 weeks
Study: NCT06764004

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Stem Cell Product
Description: Human umbilical cord stem cells and exosomes will be used.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Stem Cell Product
Description: Human umbilical cord stem cells and exosomes will be used.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleeding and clots
Description: Exosomes obtained from human umbilical cord stem cells will be used
Study: NCT06762743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam Oral Solution (Test Formulation)
Description: The drug is manufactured by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. The formulation is provided as a 300 mL: 3 g solution, with a dosage of 10 mL (100 mg) per single oral dose. The drug will be administered to participants in the fasting group during the first phase of the study and to participants in the high-fat meal group during the second phase of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam Oral Solution (Test Formulation)
Description: The drug is manufactured by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. The formulation is provided as a 300 mL: 3 g solution, with a dosage of 10 mL (100 mg) per single oral dose. The drug will be administered to participants in the fasting group during the first phase of the study and to participants in the high-fat meal group during the second phase of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam Oral Solution (Reference Formulation)
Description: The drug is manufactured by UCB Pharma S.A. under the trade name Briviact®. The formulation is provided as a 300 mL: 3 g solution, with a dosage of 10 mL (100 mg) per single oral dose. The drug will be administered to participants in the fasting group during the first phase of the study and to participants in the high-fat meal group during the second phase of the study.
Study: NCT05567744

Intervention type: OTHER
Intervention: Registry
Description: Registry
Study: NCT05732779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DOT intervention
Description: A mobile health application developed by eMocha Health Inc. facilitates asynchronous mobile video directly observed therapy (DOT) intervention, empowering users to track dose-by-dose medication adherence
Study: NCT05673577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab+cetuximab+chemotherapy
Description: Camrelizumab: 200mg vgtt q3w, 3 weeks as a cycle; Cetuximab first dose 400mg/m2, vgtt, following by 250 mg/m2 after first dose, qw, 3 weeks as a cycle; albumin paclitaxel: 125mg/m2, vgtt, d1, 8, q3w，for up to 6 cycles; cisplatin: 75mg/m2, vgtt，d1，q3w, for up to 6 cycles;~Then, in maintenance therapy, Camrelizumab: 200mg vgtt q2w; Cetuximab 500mg/m2, vgtt q2w until intolerable toxicity or disease progression
Study: NCT06412185

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM383
Description: CM383 Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM383
Description: CM383 Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM383
Description: CM383 Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM383
Description: CM383 Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM383
Description: CM383 Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM383
Description: CM383 Injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT06138106

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Natural Product Supplement
Description: Participants will have blood drawn before and one hour after consuming the natural product supplement. For 7-days the participants will perform load-bearing exercise and consume the supplement. On the final day, blood will be collected 4 hours after the final exercise bout.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Participants will have blood drawn before and one hour after consuming the placebo supplement. For 7-days the participants will perform load-bearing exercise and consume the supplement. On the final day, blood will be collected 4 hours after the final exercise bout.
Study: NCT06327529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SER 118
Description: Bean High in Phytic Acid and High in Inhibitory Polyphenols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LMP 1001
Description: Bean Low in Phytic Acid and High in Inhibitory Polyphenols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LPA 586
Description: Bean Low in Phytic Acid and Low in Inhibitory Polyphenols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KAT B1
Description: Bean High in Phytic Acid and Low in Inhibitory Polyphenols
Study: NCT04289376

Intervention type: OTHER
Group type: OTHER
Intervention: Gaze tracking - no intervention
Description: Monitor gaze as subjects watch a video
Study: NCT06762743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam Oral Solution (Reference Formulation)
Description: The drug is manufactured by UCB Pharma S.A. under the trade name Briviact®. The formulation is provided as a 300 mL: 3 g solution, with a dosage of 10 mL (100 mg) per single oral dose. The drug will be administered to participants in the fasting group during the first phase of the study and to participants in the high-fat meal group during the second phase of the study.